ILMN
Illumina, Inc.
Diagnostics & Research · Healthcare · United States
290.06
close · 2026-10-29
value
12
cheaper than peers12
quality
68
stronger fundamentals68
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| forward P/E | 47.33× | 28 |
| price to sales | 9.75× | 27 |
| price to book | 15.43× | 26 |
| EV to EBITDA | 38.93× | 15 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 32.3% | 91 |
| operating margin | 21.1% | 88 |
| revenue growth | 9.4% | 40 |
| debt to equity | 89.0% | 22 |
4 of 4 measures available
Facts
| market cap | $44B |
| free cash flow | $797.6M |
| employees | 8,600 |
| first trade | 2000-07-28 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 5.45 | -7.69 | -7.34 | -28.00 |
| free cash flow | $931.0M | $709.0M | $283.0M | $106.0M |
| net income | $850.0M | -$1.22B | -$1.16B | -$4.40B |
| revenue | $4.34B | $4.37B | $4.50B | $4.58B |
| unusual items | -$10.0M | -$1.43B | -$847.0M | -$4.53B |